ICAM1 and Alzheimer disease: Finally, in order to overcome interference of non-AD copathology on BBM interpretation, VCAM1/ICAM1 and alpha-synuclein are emerging in research as new BBMs suitable for the identification and characterization of non-AD copathology such as vascular pathology and alpha-synucleinopathy, respectively [83].